Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - Australia is recognized for its mature R&D ecosystem, established regulatory pathways, and cost-effective clinical trial environment for Cell and Gene Therapy (CAGT) products [4][5][6] - The country has over 160 ongoing industry CAGT trials, with a focus on oncology, autoimmune diseases, and cardiovascular conditions [9][12] - IQVIA is highlighted as a leading Contract Research Organization (CRO) in Australia, providing comprehensive support for CAGT products from pre-clinical to post-marketing stages [24][29] Summary by Sections Why Australia for CAGT Trials? - Australia offers a cost-effective and mature clinical research infrastructure, with high-quality data accepted by global regulators [5][6] - The regulatory framework allows for rapid trial initiation and approvals, with minimal documentation required [7][11] - The favorable AUD exchange rate and R&D tax incentives contribute to lower trial costs compared to the U.S. [7] Mature R&D Ecosystem - Australia hosts over 160 ongoing CAGT trials, with a robust clinical research infrastructure and experienced investigators [9][11] - The country has established treatment centers for complex therapies, including CAR-T, and offers end-to-end support from CDMO partners [10][11] Established and Favorable Regulatory Pathway - The Clinical Trial Notification (CTN) process allows for a fast regulatory start-up, typically taking around 7 to 10 days [14][17] - The Therapeutic Goods Administration (TGA) does not evaluate clinical trial data under the CTN scheme, focusing instead on product safety [18] IQVIA, the Leading CRO in Australia - IQVIA provides a local presence with global capabilities, supporting CAGT trials through a network of sites and a dedicated study management team [26][28] - The organization has participated in the clinical development of 17 approved CAGT products, showcasing its expertise in the field [33] Global Reach and Local Impact - IQVIA's capabilities allow for seamless integration of new countries into multi-regional development plans for CAGT products [26][30] - The company offers a comprehensive strategy for commercialization, policy shaping, and stakeholder engagement [29]

White Paper Optimizing Early-Phase Clinical Trials for Rapid, Evidence- Based Decision Making Leveraging the rapidly evolving design and delivery strategies to safely accelerate molecule advancement ELIZABETH ALLEN, PhD, Vice-President, Early Phase Development Centre of Excellence, Scientific Strategy RAYMOND COOK, MD, Vice President, Medical Strategy for Early Phase Development JOANNE EMANUEL, Senior Director, Clinical Project Management, Early Phase JOCHEN ZESCHKY, Senior Therapeutic Strategy Lead Directo ...

Key Takeaways IQVIA beat Q4 earnings and revenue estimates, delivering 9.6% EPS growth and 10.3% Y/Y revenue rise.IQV posted segment gains: R&D and Technology & Analytics grew about 10%, while Contract Sales surged 18.6%.IQVIA guided 2026 revenues at $17.15-$17.35B and reported $2B cash with $561M in Q4 free cash flow.IQVIA Holdings Analytics Inc. (IQV) has reported impressive fourth-quarter 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate.Adjusted earnings were $3.42 per share, ...

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Company ParticipantsAri Bousbib - CEODavid Windley - Managing Director and Founding memberKerri Joseph - Senior VP of Investor Relations and TreasuryMike Fedock - VP, Financial Planning and AnalysisRon Bruehlman - EVP and CFOShlomo Rosenbaum - Managing Director in the Business Services SectorConference Call ParticipantsElizabeth Anderson - Senior Managing Director and Healthcare Services Equity Research AnalystEric Coldwell - Senior Resear ...

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Company ParticipantsAri Bousbib - CEODavid Windley - Managing Director and Founding memberKerri Joseph - VP of Investor RelationsMike Fedock - VP, Financial Planning and AnalysisRon Bruehlman - EVP and CFOShlomo Rosenbaum - Managing Director in the Business Services SectorConference Call ParticipantsElizabeth Anderson - Senior Managing Director and Healthcare Services Equity Research AnalystEric Coldwell - Senior Research AnalystJustin Bow ...

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Speaker7Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Fourth Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would ...

分组1 - IQVIA Holdings reported quarterly earnings of $3.42 per share, exceeding the Zacks Consensus Estimate of $3.4 per share, and showing an increase from $3.12 per share a year ago, representing an earnings surprise of +0.50% [1] - The company achieved revenues of $4.36 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.83%, and up from $3.96 billion in the same quarter last year [2] - IQVIA has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market, losing about 10.2% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.95 on revenues of $4.04 billion, and for the current fiscal year, it is $12.93 on revenues of $17.03 billion [7] 分组3 - The Medical - Instruments industry, to which IQVIA belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for IQVIA was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

Healthcare data and clinical research provider IQVIA Holdings on Thursday forecast annual profit below Wall Street expectations, weighed down by higher interest costs, even as strong fourth-quarter re... ...

Q4 2025 Earnings Call February 5, 2026 © 2026. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. IQVIA Template (V4.0.0) 100% 50% 75% 25% Bright Blue Indigo Bright Teal Bright Green Emerald 5% Charcoal Red Legal 2 IQVIA Template (V2.1.0) 100% 50% 75% 25% This presentation should be viewed in conjunction with IQVIA's Q4 2025 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "fo ...

Exhibit 99.1 IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance RESEARCH TRIANGLE PARK, N.C. – February 5, 2026 – IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2025. "IQVIA closed 2025 with strong performance across all segments," said Ari Bousbib, chairman ...